P&G/Gillette earnings
This article was originally published in The Tan Sheet
Executive Summary
P&G expects the dilutive impact of its Gillette acquisition to reduce EPS by $.25 - $.35 in the first year after closing and $.05 -$.10 in the second year, with positive EPS growth of $.01 - $.05 in the third year, the firm says in a June 20 SEC filing. P&G's near-term strategy "must focus on the successful integration of the Gillette business and delivery of growth and cost synergies," the filing states; the firms are rumored to be mulling the divestment of certain brands to appease regulators, including products in the oral care division. P&G and Gillette recently postponed shareholder votes on the merger to July 12 and 13, respectively (1"The Tan Sheet" May 30, 2005, p. 7)...
You may also be interested in...
P&G/Gillette Integration On Track, But Shareholder Meetings Postponed
Preparations for Procter & Gamble's integration of Gillette are proceeding as scheduled, according to a May 24 filing with the SEC
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.